Table 20.
Summary of potent HCV inhibitors explored between 2011 and 2016.
| Drug type | Drug name | Current stage |
|---|---|---|
| NS3/4A inhibitor | Asunaprevir (BMS-650032), boceprevir (SCH503034), telaprevir (VX-950), paritaprevir (ABT-450), grazoprevir (MK-5172), simeprevir (TMC435), vaniprevir (MK-7009) | Approved drugs |
| Voxilaprevir (GS-9857), glecaprevir (ABT-493), danoprevir (ITMN-191, R7227), vedroprevir (GS-9451) a, faldaprevir a, narlaprevir (SCH900518) a | Clinical tests | |
| BMS-605339, MK-8831, BMS-890068 | Preclinical tests | |
| NS4B inhibitor | PTC725, piperazinone derivatives, imidazo[2,1-b]thiazole agents | Preclinical tests |
| NS5A inhibitor | Daclatasvir (BMS-790052), ledipasvir (GS-5885), ombitasvir (ABT-267), elbasvir (MK-8742), velpatasvir (GS-5816) | Approved drugs |
| Pibrentasvir (ABT-530), ravidasvir (PPI-668), GSK2336805, ruzasvir (MK-8408), EDP-239, samatasvir (IDX719) a | Clinical tests | |
| Biphenylimidazole analogues, AV4025, disulfiram | Preclinical tests | |
| NS5B nucleoside inhibitor | Sofosbuvir (GS-7977, PSI-7977) | Approved drugs |
| MK-3682, mericitabine (RG7128) a, GS-6620 a, JNJ-54257099 a | Clinical tests | |
| NS5B non-nucleoside inhibitor | Dasabuvir (ABT-333) | Approved drugs |
| Beclabuvir (BMS-791325), TMC647055, GS-9669, filibuvira, lomibuvir (VX-222)a, tegobuvir (GS-9190)a, deleobuvir (BI207127) a | Clinical tests | |
| 6-aminoquinolone derivatives, pyrazolobenzothiazines | Preclinical tests | |
| E1/E2, p7 inhibitor | Adamantane, chlorcyclizine, cynaropicrin, flunarizine, grosheimol, saikosaponin b2, rimantadine, benzimidazole derivative B5, | Preclinical tests |
| Immuno-stimulator and cellular protein inhibitor | ITX-5061, alisporivir (DEB025) a | Clinical tests |
| NIM258, MA026, soraphen A, isothiazolo[5,4-b]pyridines, phenyl–pyrrolidine derivatives, bis-amide derivatives | Preclinical tests |
a
Discontinued compounds. See details in a recent review addressing the discontinued HCV drugs (Gentile et al., 2015).